Activity–lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments

https://doi.org/10.1016/j.bmcl.2013.05.019Get rights and content

Abstract

A series of alkyloxyquinoline derivatives has been developed to evaluate the relationship between P-gp potency and lipophilicity. The results show a satisfactory lipophilicity-activity correlation although a series of derivatives showing higher P-gp potency is needed in order to confirm this hypothesis.

References and notes (15)

  • P. Labrie et al.

    Bioorg. Med. Chem.

    (2007)
  • N.A. Colabufo et al.

    Bioorg. Med. Chem.

    (2008)
  • N.A. Colabufo et al.

    Bioorg. Med. Chem.

    (2008)
  • M. Contino et al.

    Bioorg. Med. Chem. Lett.

    (2013)
  • V.W. Pike

    Trends Pharmacol. Sci.

    (2009)
  • M.M. Gottesman et al.

    Nat. Rev. Cancer

    (2002)
  • S.V. Ambudkar et al.

    Annu. Rev. Pharmacol. Toxicol.

    (1999)
There are more references available in the full text version of this article.

Cited by (12)

  • One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells

    2020, European Journal of Medicinal Chemistry
    Citation Excerpt :

    This approach has been used in cancer therapy to overcome multidrug resistance (MDR), i.e. the simultaneous resistance to multiple chemotherapeutic drugs because of their efflux via P-gp [9–11] and may be therefore an effective strategy in oncological settings. It has been several years since the authors started dealing with the development of highly potent and selective P-gp ligands, with the aim to hit the undesirable effect due to P-gp mediated efflux of unrelated chemical entities acting as drugs [12–28]. Starting from our lead compound MC70, bearing a tetrahydroisoquinoline scaffold, displaying high potency vs P-gp [14], we proceeded in the design and biological evaluation of several series of P-gp compounds identifying compound 1 that emerged as a P-gp ligand able to overcome MDR in cancer stem cells (Chart 1) [25].

  • Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update

    2020, Drug Resistance Updates
    Citation Excerpt :

    Furthermore, compound 115, at 2.5 μM, significantly increased the efficacy of vincristine, paclitaxel, and doxorubicin in KBvin cancer cells, with RF values of 246.4-, 38.7-, and 5.2-fold, respectively. Given that high lipophilicity is an essential property for compounds to produce P-gp efficacy (Contino et al., 2013), Tardia et al., synthesized a series of N-biphenyl-benzamide derivatives as P-gp inhibitors, whose lipophilicity was modulated by the introduction of methoxyl groups to form an intramolecular hydrogen bond (Tardia et al., 2014). Eleven out of 21 compounds were identified as dual inhibitors of P-gp and MRP1, whereas the majority of the compounds were more potent in inhibiting P-gp than MRP1.

  • Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2

    2019, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Two major findings of our research are the dual ABCB1/ABCG2 inhibitors 99 and 106. Since research within the last two decades was focused on the development of potent and selective inhibitors of either ABCB1 [58–62], ABCC1 [37,38,63,64], or ABCG2 [49,53–57], there is not enough experience available regarding dual ABCB1/ABCG2 MDR reversers. Also, most dual ABCB1/ABCG2 inhibitors have not been investigated regarding their MDR reversing property.

View all citing articles on Scopus
View full text